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Just Imagine
• You are a 40 year old male with no significant medical
history that you know of but you don’t really go see
physicians because you’re your own doctor

• You were playing outside with your 10 year old and
suddenly fell and couldn’t move your right side

In the Emergency Room
• You arrived to the ED via EMS
• Your blood pressure was found to be 205/96
• Your blood sugar was 275
• The doctors rushed you to the cat scan and thankfully
there was no evidence of blood on your brain
• You can now move your right side off the bed and you
start thinking that you are “out of the woods”

• The ED gave a little hydralazine to get the blood
pressure down.
• About 2 hours later you now cannot move your right
side at all

Introduction

Burden of Stroke
• In 2015 the total cost in the US was approximately
$66.3 billion
• Projected to increase to $143 billion by 2035
• Burden of stroke is on both the stroke survivor and
the family/caregiver
Adeoye, O. et al. Recommendations for the Establishment of Stroke Systems of Care: A 2019 Update. Stroke 2019:50:e187e210.

OBJECTIVES
• Review up to date secondary stroke prevention
guidelines based on stroke etiology
• Discuss barriers preventing appropriate risk factor
management amongst different ethnic groups
• Introduce interventions that may increase better risk
factor control

Carotid Stenosis

CREST: Carotid Revascularization
Endarterectomy Versus Stenting Trial

• Randomized
• >50% symptomatic stenosis
• >50% asymptomatic stenosis

Bottom line
• Based on CREST: Overall safety and efficacy largely the
same for CAS and CEA
• no difference for MAJOR strokes

• Younger (< 69) patients did better with stent
• Older (> 70) patients did better with surgery
• MI greater concern with CEA
• Stroke greater concern with CAS
• No significant sex differences

Cardiogenic Emboli
• Responsible for ≈20% of ischemic strokes
• Common sources of emboli
– Non-valvular atrial fibrillation (~50%)
– Valvular heart disease (~25%)
– Left ventricular mural thrombus

• Congestive Heart Failure increases stroke
risk by 2 or 3 fold

Atrial Fibrillation
•
•
•
•

AF affects > 2.7 million Americans
It becomes more prevalent with age
Stroke is the principal adverse consequence
In the US, AF is responsible for >70,000
stroke each year (10%-12% of all ischemic
strokes
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Warfarin therapy
• Multiple clinical trial established warfarin as
the preferred choice for primary stroke
prevention in patients with AF
• RR rate of 68%
• 32 ischemic stroke will be prevented each
year for every 1000 patients treated
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New oral anticoagulants
• RE-LY (2009): direct thrombin inhibitor dabigatran
110mg and 150mg twice daily vs. adjusted-dose
warfarin (open-label) in 18,113 patients.
• AVERROES (2011): factor Xa inhibitor apixaban 5mg
twice daily vs. aspirin (double-blind) in 5,599 patients.
• ROCKET AF (2011): factor Xa inhibitor rivaroxaban
20mg daily vs. adjusted-dose warfarin (double-blind)
in 14,264 patients.
• ARISTOTLE (2011): factor Xa inhibitor apixaban 5mg
twice daily vs. adjusted-dose warfarin (double-blind) in
18,201 patients

Detection of occult AF
• 10% of patients with acute ischemic
stroke or TIA have new AF during hospital
admission
• In additional 10-15%, AF is detected
within 30 days with MCOT
• Pacemaker interrogation identified 28%
incidence of occult AF
• Implantable cardiac rhythm devices
identify 10-28% occult AF
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ASA/AHA Guidelines
- For patients with no other cause of stroke, prolonged cardiac
monitoring (about 30 days) is reasonable within 6 months of the
event (new recommendation)
- VKA therapy (Class I; Level of Evidence A), apixaban (Class I; Level of
Evidence A), and dabigatran (Class I; Level of Evidence B) are all
indicated for the prevention of recurrent stroke in patients with
nonvalvular AF
- Rivaroxaban is reasonable for the prevention of recurrent stroke in
patients with nonvalvular AF (Class IIa; Level of Evidence B).
(New recommendation)
- Target INR of 2.5 is recommended (range, 2.0–3.0)
(Class I; Level of Evidence A).

Small Vessel Disease
• Most common cause of small vessel (lacunar) strokes
in Hypertension
• Other causes
• Hypercholesterolemia
• Diabetes
• Smoking

HYPERTENSION
• Several patients have undiagnosed hypertension
(about 70 million Americans have HTN)
• Treatment of HTN is the most important intervention
for secondary prevention of ischemic stroke
• Blood pressure management is associated with a risk
reduction of 30-40%

AHA/ASA GUIDELINES

Hypertension (cont’d)
• Life Style Modification:
• Diet
•
•
•
•

Fruits
Vegetables
Nuts
Low-fat dairy

• Exercise
• Limited alcohol consumption

EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION (DASH) DIET
N Engl J Med, Vol. 344, No. 1 January 4, 2001

Dyslipidemia

Impact of Statin therapy
It has been shown that pre- and post-stroke treatment with
statins have a 24% reduction in mortality
High intensity treatment (atorvastatin 40mg or 80mg) – in high
risk patient
Low intensity treatment (atorvastatin 10mg) – in low risk
patients

Flach, C et al. The impact of Pre- and Post-stroke statin use ion stroke severity and long-term outcomes: A
population based cohort. Cerebrovac Dis 2019;47(5-6):260-267

DIABETES/PRE-DIABETES
• Burden of diabetes is increasing both in developed and
developing countries
• Prevalence in the US
• 3.7% age 20-44
• 27% >65

• Higher in Hispanics and Blacks
• Diabetes – defined as HgA1c >6.5% or 2hr GTT sugar >200
• Pre-diabetes
• Impaired fasting glucose (100-125)
• Impaired glucose tolerance (2hr GTT with sugar >140-199)
• Fluctuating Glycated HgA1c between 5.7% and 6.4%

Diabetes
• Diabetes and Hypertension –
– American Diabetes Association recommends
using an ACE-I or ARB
1

• Diabetes and Hyperlipidemia –
– LDL-cholesterol should be less than 70

2

– Heart Protection Study showed that diabetics with total cholesterol >135 that were
treated with
simvastatin had a 28% reduction of ischemic stroke compared to 4.7%
3
in placebo

• Goal HgA1c <7%
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1.

Diabetes Care. 2004;27:S1-S143 2. Circulation 2004: 110:227-239

3. Sacco et al. Stroke 2006;37:577-617

Obstructive Sleep Apnea
- Present in about 50-75% of patients with stroke or TIA
- About 70-80% of the patients with sleep apnea are neither diagnosed or
treated
- American Academy of Sleep Medicine Adult OSA Task force recommends
that stroke or TIA patients with symptoms undergo sleep study
- Multiple RCTs have been done with mixed results but trends towards
treatment with CPAP showing improvement in outcomes in stroke
patients
- The newer recommendations is that stroke and TIA patients undergo
sleep study
And treatment with CPAP might be considered in this population

Secondary Prevention
Antiplatelet Agents
The BIG debate for years was
Aspirin vs Plavix vs Dipyridamole
However recent studies show benefit of dual
antiplatelet therapy

CHANCE and POINT Trials
(Clopidogrel in High-risk Patients with Acute Non-disabiling Cerebrovascular Events
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke)
Both studies looked at treatment with Aspirin and Clopidogrel vs Aspirin alone
Included were patients with minor strokes (NIHSS ≤ 3 or TIA with ABCD2 score ≥ 4
Conclusion - benefit of DAPT for 21 days.
Recommendation – load patient with 300mg clopidogrel and then 75mg daily with
aspirin 81mg daily for 21 days then aspirin alone
Pooled analysis of the studies showed a higher rate of hemorrhage after 90days
with DAPT and net clinical benefit occurred within the first 21 days
Pan, Y et al. Outcomes associated with clopidogrel-aspirin use in Minor Stroke or TIA, a pooled analysis.
Jama Neurology August 19, 2019

Back to our initial case
• That patient was started on an ACE-inhibitor while in
the hospital but decided they didn’t need it at home
because they were going to “watch their diet”

• They were also found to have a HgA1c of 7.4% but
thought that had to be a mistake and was only
elevated due to the acute stress of having a stroke

Challenges in Secondary Stroke
Prevention

• Factors that have played a role in health
disparities for stroke prevention
• Race and Ethnicity
• Socioeconomic status
• Level of Education
• Access to Health Care

Blood Pressure Control
• Only about 40-50% of patients have good blood
pressure control
• Some suggested factors that may play a role in good
blood pressure control are the following:
•
•
•
•
•
•

Biological, social and cultural differences
Differences in health care provider and health care systems
Types of medications given
Insufficient attention by health care providers
Adherence to medications
Lack of resources to make recommended lifestyle changes
Race-ethnicity on blood pressure control after ischemic stroke: a prospective cohort study
Journal of the American Society of Hypertension, 2017-01-01, Volume 11, Issue 1, Pages 38-44

Other factors
• Age – elderly were less likely to get
Anticoagulation for Afib and stroke prevention
• Swedish study showed that antihypertensive
meds for stroke prevention and outpatient
follow-up was less in university based centers
• Australian study showed that increased
incidences of CVD events in less educated
population
1. Diagnostic Procedures, Treatments, and Outcomes in Stroke Patients Admitted to Different Types of Hospitals
2. Socioeconomic Inequalities in the Prescription of Oral Anticoagulants in Stroke Patients With Atrial Fibrillation
3. Socioeconomic variation in incidence of primary and secondary major cardiovascular disease events: an Australian
population-based prospective cohort study

How to Improve Secondary Stroke
Prevention: Old fashion education?
• Inner-city New York study
– Blacks and latinos from low income families
– Attended peer-led (stroke survivors), communitybased, stroke prevention self-management group
workshop
– Found better control of blood pressure but not other
risk factors in this group compared to control group
– Control group was a group of individuals who were
handed pamphlets about stroke prevention and had
to do it on their own
Effect of Peer Education on Stroke Prevention: The Prevent Recurrence of All Inner-City Strokes Through Education Randomized
Controlled Trial
Stroke. 2014 Nov;45(11):3330-6

Can Smart Phones Help?
• Several Apps are available to help patients
monitor blood pressure, physical activity,
weight changes etc.
• We should use technology if we can

Functional and Integrative Medicine
• New branch of medicine
• Use of Primary care physician, dietician, psychiatrist
(psychologist), chiropractors, acupuncture,
supplementary medicine
• Some of the neurological diseases this has been used
for are Parkinson patients, ALS, Fibromyalgia, Chronic
pain (headache) and are now considering patients with
recurrent strokes who are having a hard time getting
risk factors under control

CONCLUSION
• Secondary Prevention should focus on the primary
etiology of ischemic stroke
• Large Vessel Atherosclerosis: CEA or Stenting and
antiplatelet + risk reduction
• Cardioembolic: A-fib - Warfarin, NOAC
• Small Vessel Disease: Antiplatelet agent + Control of
HTN, DM, and ↑ Lipids (DAPT for 21 days)
• Cryptogenic stroke ( ~30%) – may use long-term event
monitoring if suspect paroxsymal a-fib + antiplatelet
agent

Ischemic Stroke Prevention
It Takes A Team To Prevent Further Ischemic Strokes:
• Neurology
• Neurosurgery
• Neuro-Interventional Radiologists
• Cardiologists
• Primary Care Physician

Conclusion
• Newer techniques are being tested to help with
getting better control of risk factors for stroke
• Life style changes and alternative medicine may
make a significant difference in reducing the 25% of
secondary strokes
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THANK YOU

